AZ bets big on biologics with $285M Swedish facility

AstraZeneca ($AZN), trying to turn its sales performance around, has some biologics launches on the horizon. But to accommodate them, it needs more manufacturing capacity, and it thinks a new $285 million plant in Sweden will do the trick. More from FiercePharma

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.